Metabolic surgery: the cutting edge of diabetes care

摘要

International guidelines recognize surgery as a standard treatment option for type 2 diabetes mellitus, including in mildly obese individuals who fail to respond to conventional therapies. A new report from the STAMPEDE trial now provides further evidence and emphasizes the need for health care regulators to introduce appropriate reimbursement policies for metabolic surgery.